Centre Francois Baclesse

Quick facts

Marketed products

• ARM A : IV iron + epoietin zeta · Hematology/Oncology
  This combination therapy replenishes iron stores and stimulates red blood cell production to treat chemotherapy-induced anemia.
• ARM B: IV iron + epoietin zeta sequence · Hematology/Oncology
  This combination therapy replenishes iron stores and stimulates red blood cell production to treat anemia.
• ARM C : single epoietin zeta
• cabozantinib and nivolumab
• Essential oils

Phase 3 pipeline

• CHEMOTHERAPY ONLY · Oncology
  This is a general chemotherapy designation rather than a specific drug, referring to cytotoxic agents that kill rapidly dividing cancer cells.
• Hormonotherapy · Other
• Ialuset® · Dermatology / Wound Care
  Ialuset is a topical wound healing agent that promotes tissue repair and epithelialization through enhanced cellular proliferation and collagen deposition.
• Systematic RAI-treatment · Oncology
  Systematic RAI-treatment involves the use of radioactive iodine to target and destroy thyroid cancer cells.

Phase 2 pipeline

• perioperative treatment

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Centre Francois Baclesse portfolio CI brief
• Centre Francois Baclesse pipeline updates RSS